[go: up one dir, main page]

AU2001236886A1 - Use of relaxin to treat diseases related to vasoconstriction - Google Patents

Use of relaxin to treat diseases related to vasoconstriction

Info

Publication number
AU2001236886A1
AU2001236886A1 AU2001236886A AU3688601A AU2001236886A1 AU 2001236886 A1 AU2001236886 A1 AU 2001236886A1 AU 2001236886 A AU2001236886 A AU 2001236886A AU 3688601 A AU3688601 A AU 3688601A AU 2001236886 A1 AU2001236886 A1 AU 2001236886A1
Authority
AU
Australia
Prior art keywords
relaxin
vasoconstriction
diseases related
treat diseases
vasodilation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236886A
Inventor
Kirk P. Conrad
Xinfan Huang
Martyn Lewis
Carol A. Tozzi
Elaine N. Unemori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicine And Dentistry Of New Jersey-Robert Wood Johnson Medical School, University of
Connetics Corp
University of Pittsburgh
Original Assignee
Rutgers State University of New Jersey
Connetics Corp
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey, Connetics Corp, University of Pittsburgh filed Critical Rutgers State University of New Jersey
Publication of AU2001236886A1 publication Critical patent/AU2001236886A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to methods of treating diseases related to vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is therefore useful in treating a wide variety of diseases relating to vasoconstriction.
AU2001236886A 2000-02-09 2001-02-09 Use of relaxin to treat diseases related to vasoconstriction Abandoned AU2001236886A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18140800P 2000-02-09 2000-02-09
US60181408 2000-02-09
US20028400P 2000-04-28 2000-04-28
US60200284 2000-04-28
US24221600P 2000-10-20 2000-10-20
US60242216 2000-10-20
PCT/US2001/004370 WO2001058468A1 (en) 2000-02-09 2001-02-09 Use of relaxin to treat diseases related to vasoconstriction

Publications (1)

Publication Number Publication Date
AU2001236886A1 true AU2001236886A1 (en) 2001-08-20

Family

ID=27391410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236886A Abandoned AU2001236886A1 (en) 2000-02-09 2001-02-09 Use of relaxin to treat diseases related to vasoconstriction

Country Status (7)

Country Link
US (2) US6723702B2 (en)
EP (1) EP1253929B1 (en)
AT (1) ATE362770T1 (en)
AU (1) AU2001236886A1 (en)
CA (1) CA2397200C (en)
DE (1) DE60128540T2 (en)
WO (1) WO2001058468A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60131644T2 (en) * 2000-05-09 2008-10-30 Nitromed, Inc., Lexington INFRARED THERMOGRAPHY AND TREATMENT OF SEXUAL DYSFUNCTIONS
EP1889633B1 (en) * 2000-06-27 2011-10-26 AnGes MG, Inc. Medicinal compositions for angiogenic therapy
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ITFI20030328A1 (en) * 2003-12-24 2005-06-25 Mario Bigazzi USE OF RELAXIN AS ADIUVANT IN DIFFERENTIATION
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
WO2005089489A2 (en) * 2004-03-19 2005-09-29 Bas Medical, Inc. Use of relaxin to increase arterial compliance
US20070202080A1 (en) * 2004-03-30 2007-08-30 Industry-University Cooperation Foundation Yonsei Gene Delivery System Containing Relaxin Gene And Pharmaceutical Composition Using Relaxin
EP1753449A4 (en) 2004-04-30 2009-09-23 Corthera Inc Methods and compositions for control of fetal growth via modulation of relaxin
US20090088374A1 (en) * 2005-01-07 2009-04-02 Judithann Lee Novel use
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
CN101277704A (en) * 2005-04-12 2008-10-01 因特拉迪格姆公司 Compositions and methods of RNAi therapeutics for treating cancer and other neovascular diseases
US20060281669A1 (en) * 2005-06-13 2006-12-14 Yue Samuel K Method and compositions for the treatment of diabetes and related complications
WO2007027168A1 (en) * 2005-08-29 2007-03-08 Carrier Corporation Compressor muffler
CN101505744A (en) * 2006-07-25 2009-08-12 爱尔康研究有限公司 Antagonists of endothelial differentiation gene subfamily 3 (EDG-3, S1P3) receptors for the prevention and treatment of ocular disorders
CN101679095B (en) * 2007-05-11 2012-09-05 康宁股份有限公司 Control of isopipe sag with improved end support conditions
EA022948B1 (en) 2008-05-16 2016-03-31 Кортера, Инк. Treatment of dyspnea associated with acute heart failure with relaxin
AU2009246333B2 (en) * 2008-05-16 2013-05-09 Corthera, Inc. Method of promoting wound healing
BRPI0920897A2 (en) * 2008-11-24 2015-12-29 Corthera Inc prognosis and prevention of preeclampsia
WO2010105081A1 (en) * 2009-03-13 2010-09-16 Medtronic, Inc. Method of treating heart failure
JP5970380B2 (en) 2010-03-10 2016-08-17 ザ ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Regulation of aquaporins by relaxin
EP2605789B1 (en) 2010-08-17 2019-06-05 Ambrx, Inc. Modified relaxin polypeptides and their uses
WO2013004607A1 (en) * 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
US9434780B2 (en) * 2011-08-04 2016-09-06 Relaxera Pharma Gmbh & Co. Kg I.G. Process for preparing human relaxin-2
WO2013033324A2 (en) * 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US9393288B2 (en) 2012-05-29 2016-07-19 The University Of Vermont And State Agricultural College Methods of treating diseases associated with PPARγ
CN104507487A (en) * 2012-07-31 2015-04-08 诺华股份有限公司 Treating inflammation using serelaxin
US9381231B2 (en) * 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
WO2017201340A2 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
BR112023007024A2 (en) * 2020-10-15 2023-10-03 Univ Northeastern CELLS MODIFIED FOR INCREASED COLLAGEN PRODUCTION
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003917A (en) * 1959-01-14 1961-10-10 Nat Drug Co Wound healing composition
DE3236264A1 (en) 1982-09-30 1984-04-05 Serono Pharmazeutische Präparate GmbH, 7800 Freiburg METHOD FOR OBTAINING RELAXIN
CH661662A5 (en) * 1984-04-16 1987-08-14 Georg L Prof Dr Floersheim Product for the treatment of the skin and of the connective tissue
US4910317A (en) * 1987-07-14 1990-03-20 Warner-Lambert Company Benzofurans and benzothiophenes having antiallergic activity and method of use thereof
AU626840B2 (en) * 1988-02-26 1992-08-13 Genentech Inc. Human relaxin formulation
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
US5952296A (en) * 1993-07-27 1999-09-14 Bigazzi; Mario Method of using relaxin as therapeutic or preventing agent
EP0722334A1 (en) 1993-09-14 1996-07-24 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting blood vessel blockage using a polypeptide
AU6777196A (en) * 1995-08-15 1997-03-12 Connective Therapeutics Inc. Method of promoting angiogenesis
US6251863B1 (en) * 1998-09-08 2001-06-26 Samuel K. Yue Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin

Also Published As

Publication number Publication date
ATE362770T1 (en) 2007-06-15
EP1253929A4 (en) 2003-03-05
CA2397200A1 (en) 2001-08-16
US20040266685A1 (en) 2004-12-30
EP1253929B1 (en) 2007-05-23
WO2001058468A1 (en) 2001-08-16
EP1253929A1 (en) 2002-11-06
US20020019349A1 (en) 2002-02-14
DE60128540D1 (en) 2007-07-05
CA2397200C (en) 2010-11-23
HK1051001A1 (en) 2003-07-18
DE60128540T2 (en) 2008-01-31
US6723702B2 (en) 2004-04-20

Similar Documents

Publication Publication Date Title
AU2001236886A1 (en) Use of relaxin to treat diseases related to vasoconstriction
NZ520015A (en) Hydroxide-releasing agents as skin permeation enhancers
EP1086702A3 (en) Method for reduction of headache pain
ES2275716T3 (en) PHARMACEUTICAL COMPOSITION OF TRANSDERMAL LIBERATION.
GB0105772D0 (en) Use
PL370795A1 (en) Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne
MXPA04000654A (en) Dermal therapy using phosphate derivatives of electron transfer agents.
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
TR200101120T2 (en) Serine protease inhibitor
HRP20040042A2 (en) Substituted oxazolidinones for combinational therapy
IL154693A (en) Use of a testosterone gel for manufacturing a medicament for treating a testosterone deficient disorder in woman
WO1999045920A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO2002038171A3 (en) METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF α-L-IDURONIDASE
AU2088597A (en) Antagonism of endothelin actions
WO2000064405A3 (en) Treating hair by targeting enzymes
BR0109515A (en) Apomorphine Derivatives and Methods for Their Use
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
IL167890A (en) Use of a chorionic gonadotropin in the preparation of a medicament for treating a chronic pelvic pain syndrome
SE0004101D0 (en) New use
AP1896A (en) The method of treating cancer
EP1854476A3 (en) Use of relaxin to treat diseases related to vasoconstriction
WO2001041747A3 (en) Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer
ID26965A (en) MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS